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Abstract
Background: Stereotactic radiosurgery (SRS) has emerged as a common adjuvant modality used with surgery for
resectable brain metastases (BMs). However, the optimal sequence of the multi-modality therapy has not been
established. The goal of the study is to evaluate 6-month local control utilizing pre-operative SRS followed by
surgical resection for patients with 1–4 brain metastases.
Methods: This prospective, single arm, phase II trial will recruit patients with up to 4 brain metastases and at least
one resectable lesion. All lesions will be treated with SRS and symptomatic lesions will be resected within 1–4 days
after SRS. Patients will be monitored for 6-month local control, in-brain progression free survival, distant in-brain
failure, rate of leptomeningeal spread, radiation necrosis and overall survival. Additionally, we will also perform
correlative radiobiological molecular studies to assess the effect of radiation dosing on the tumor tissue and clinical
outcomes. We expect that pre-operative SRS to the gross tumor prior to surgical resection will improve local
control and decrease leptomeningeal failure.
Discussion: Our study is the second prospective trial to investigate the efficacy of pre-operative SRS in the treatment
of multiple BMs. In addition, the correlative molecular studies will be the first to investigate early response of BMs at a
cellular and genetic level in response to radiation doses and potentially provide molecular prognostic markers for local
control and overall survival.
Trial registration: Clinicaltrials.gov identifier: NCT03398694 (registration date: January 12, 2018).
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Issue Section
Research – Human – Study protocols
GENERAL INFORMATION
Pre-operative stereotactic radiosurgery followed by
resection for patients with brain metastases
Study Dates
January 12, 2018, currently recruiting
Investigators: Table 1
 Research Site: IU Health Methodist Hospital
1701 N Senate Ave. Indianapolis IN 46202
Phone # 317 962-2000
Background
Incidence of brain metastases (BMs) is increasing with im-
proved systemic therapies, many of which have a limited
impact on intracranial disease. [1, 2] Historically a combin-
ation of surgical removal with subsequent whole brain radi-
ation therapy (WBRT) was the gold standard for managing
patients with a single, large BM and WBRT alone for pa-
tients with multiple metastases. [3, 4] Recent advances in
the systemic treatment of various cancers have resulted in
long-term survivors. [1, 2, 5] WBRT is associated with
debilitating neurocognitive dysfunction, which results in
significant impairment in the quality of life of long-term
survivors. [6–9] As a result, current practice patterns
shifted away from use of WBRT for oligo-metastasis,
defined as limited number of BMs, reserving WBRT as sal-
vage therapy or for disseminated BMs. [9, 10] Stereotactic
radiosurgery (SRS) delivers high dose of radiation in a
highly conformal way to relatively small target (< 3 cm) with
minimal radiation to the surrounding normal tissue. [11]
Since its conception, SRS emerged as a leading modality to
treat BMs in variety of clinical scenarios including a boost
with WBRT, as definitive treatment alone for patients with
limited number of BMs and as an adjuvant treatment
modality in pre- or post-operative setting. [12–14] Many
tumors, regardless of whether they are radiosensitive or
resistant, single or multiple, can be adequately managed
with SRS. [10, 11, 15]
Although there has been no consensus on combination
therapy with surgery and SRS [16, 17], surgical resection
continues to play an important role in patients with a lim-
ited number of BMs and relatively good performance sta-
tus where: 1) pathological diagnosis is needed, 2) a large
BM (> 2 cm) causing significant mass effect necessitating
direct decompression, and/or 3) neurological signs and
symptoms refractory to corticosteroid management. [18,
19] Therefore, for patients with 1–4 BMs, especially in the
above mentioned scenarios, adjuvant radiosurgery for
surgically resected lesions is a common practice to achieve
high LC. [9, 10]
Several clinical studies evaluating the role of
post-operative SRS in management of BMs concluded
that SRS is a safe and effective adjuvant treatment strat-
egy for BMs (Table 2). A systematic review of 14 studies
involving 629 patients treated with SRS after surgical
Table 1 Investigators Details
Name Title Role Address
Gordon A. Watson MD, PhD Associate Professor of Clinical
Radiation Oncology
Principle Investigator (Clinical Trial) 535 Barnhill Drive
RT 041 RAON
Indianapolis IN 46202
Phone # 317–962-3172
Mahua Dey MD Assistant Professor of
Neurological Surgery
Adjunct Assistant Professor of
Microbiology and Immunology
Co-Investigator (Clinical Trial)
Principle Investigator (Correlative
Radiobiological Analysis)
Dey Laboratory
Indiana University School
of Medicine
Neuroscience Research Building
320W 15th Street NB 400A
Indianapolis IN 46202
Phone # 317–274-2601
Alexander O Vortmeyer MD, PhD Professor of Clinical Pathology
and Laboratory Medicine
Co-Investigator (Clinical Trial and
Correlative Radiobiological Analysis)
Pathology and Laboratory Med
IU Health Pathology Laboratory
350 W 11th Street Room 4034
Indianapolis IN 46202
Phone # 317–274-1618
Namita Agarwal MD Resident Physician of Radiation Oncology Co-Investigator (Clinical Trial) 535 Barnhill Drive
RT 041 RAON
Indianapolis IN 46202
Phone # 317–962-3172
Sandra Althouse MS Department of Radiation Oncology Statistician 535 Barnhill Drive
RT 041 RAON
Indianapolis IN 46202
Phone # 317–962-3172
Huff et al. Radiation Oncology          (2018) 13:252 Page 2 of 10
resection showed pooled LC rate of 83%, distant intra-
cranial failure of 49% and need for salvage WBRT in
29% of cases. [20] In addition, time to salvage therapy
from initial resection was found to be 8.4 months and
10–33% of patients suffered cavity-SRS induced compli-
cations such as radiation-induced edema in 43% and
radiation necrosis (RN) in 23%. [20] Two recently pub-
lished phase III trials of post-operative SRS by Mahajan
et al. and Brown et al. demonstrated local control effi-
cacy and neurocognitive preservation compared with
WBRT, respectively. [9, 21] Mahajan et al. prospectively
randomized 132 patients in a single institution phase III
study comparing observation and post-operative SRS
and showed a significant improvement in local tumor
recurrence-free rate at 12-month in post-operative SRS
arm (72%) compared to observation arm (43%). [21] In
the same journal issue, Brown et al. reported a multi
-center prospective randomized phase III study to com-
pare the post-operative SRS and WBRT in a total of 194
patients and observed similar overall survival but signifi-
cantly improved neurocognition in post-operative SRS
compared with WBRT. [9] Interestingly, their secondary
endpoint analysis demonstrated a lower surgical bed and
local control rate as compared to data previously re-
ported. [9, 21] With a 6-month surgical bed control of
80.4% and an estimated 60.5% at 12-month, the author
discussed that lower LC rate after SRS could be due to
falsely elevated frequency of recurrence by including
Fig. 1 Flow chart describing the clinical trial study design
Table 2 Published studies of Post-op SRS after Metastases Resection
Study Treatment Modalities Number of Patients Median survival (months) LR (%) DBF (%)
Bahl, 2006 [36] Op + SRS/fSRT 7 8.9 57.1 14.3
Kim, 2006 [37] Op + GKRS 79 16 5.1 NA
Soltys, 2008 [22] Op + CK 72 15.1 21 49.2
Iwai, 2008 [38] Op + GKRS 21 20 23.8 47.6
Mathieu, 2008 [39] Op + GKRS 40 13 27 54.1
Limbrick, 2009 [40] Op + GKRS 15 20 20 60
Jagannathan, 2009 [41] Op + GKRS 47 11 6.4 72.3
Robbins, 2012 [42] Op + SRS 85 12.1 18.8 55.3
Johnson, 2016 [43] Op + GKRS 112 12.9 15.6 NA
Brown, 2017 [9] Op + SRS 98 12.2 19.6 (6 m) NA
Mahajan, 2017 [21] Op + SRS 63 17 28 58
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“pseudoprogression” on imaging and patients and tumor
mark-up differences between trials. [9] Although there
has been some discrepancy in the literature regarding to
local control rates in patients receiving post-operative
SRS (Table 2), these studies nevertheless support the
combination use of surgery and SRS as an effective way
to treat brain oligometastasis to delay WBRT and the as-
sociated neurocognitive and quality of life decline.
The drawbacks for post-operative SRS include the
need for cavity margin expansion, the unpredictability of
patients’ postoperative course and potential delay in SRS
treatment after surgery. Soltys et al. analyzed 76 post-op-
erative SRS cases and demonstrated that increasing con-
formality index significantly correlated with improved
LC and concluded that a 2-mm margin should be used
around the resection cavity due to the possible imprecise
nature of defining the target volume in a post-surgical
setting. [22] Therefore, clinicians began to investigate an
alternative paradigm of using preoperative SRS to
reach excellent local control and preserve cognitive
function.
Atalar et al. retrospectively analyzed the risk of lepto-
meningeal disease (LMD) in 175 patients with BMs
treated with post-operative SRS and found that 13% devel-
oped LMD 5months following SRS. [23] In Mahajan’s
study, the LMD reached 28% at 12month in post-opera-
tive SRS arm as compared to 16% in observation arm,
though the difference did not reach statistical significance.
It was, therefore, hypothesized that pre-resection SRS
would improve the risk of LMD by sterilizing microscopic,
dislodged tumor cells to prevent spread during surgery.
[23, 24] In addition, another potential advantage of
pre-operative SRS is a theoretical increased response to
radiation due to intact vasculature and greater peri-tu-
moral oxygen content. [25–27] Studies have shown that
lower doses of radiation are required for tumor control
when the tumor has an intact blood supply and is
oxygenated. This is due to radiation-induced DNA dam-
age that ionizes oxygen molecules and generates oxygen
-based free radicals which in turn damage nearby DNA
resulting in tumor killing. [25, 26] In the setting of BMs, it
is plausible that lower radiation doses are needed to con-
trol microscopic disease if the SRS is given prior to
surgery. [26]
The first pre-operative SRS study was published by Asher
et al where 47 patients were treated consecutively with neo-
adjuvant SRS before surgical resection, with 24 of those
patients analyzed as part of a prospective trial, and the re-
sults showed 6-month and 12-month LC rate of 97.8 and
85.6% respectively (Table 3). [28] Subsequently Patel et al
performed a multi-institutional retrospective comparison of
outcomes and toxicities for pre-operative SRS compared to
post-operative SRS for 180 patients. [29] The planning tar-
get volume (PTV) of pre-operative SRS had 0mm margin
expansion from gross tumor volume (GTV) compared to
2mm margin for PTV of post-operative SRS. The study did
not note any statistical difference in the rates of local recur-
rence, distant brain recurrence, and OS but the
pre-operative SRS cohort demonstrated significantly lower
rates of symptomatic RN (4.9% vs. 16.4%, p = 0.01) and
LMD (3.2% vs. 16.6%, p = 0.01) than their post-operative
SRS counterpart. [29] The abstract of an updated retro-
spective analysis of 117 patients with 125 lesions treated
with pre-op SRS is now available online (https://www.red-
journal.org/article/S0360-3016(18)31346-4/fulltext) and re-
ported the 1 and 2-year cavity LC rate to be 80.1 and
74.9%, distant in-brain failure (DBF): 45.3 and 60.2%, and
LMD: 4.3 and 4.3%, respectively. Nevertheless, the results
were likely limited by some intrinsic selection bias, as the
two retrospective cohort groups were statistically different
in their baseline performance status (Figure 1).
In this prospective phase II trial, we will establish the
efficacy of pre-operative SRS in local disease control.
Since the tumor will be resected within 4 days of the de-
livery of the radiation, we will treat lesions up to 5 cm in
size with SRS. In addition, there is no available published
literature that describes early tumor cell molecular
responses to radiosurgical doses of ionizing radiation in
Table 3 Published studies of Pre-op SRS prior to Metastases Resection
Study Treatment
Modalities
(Number of
patients)
Target Median
survival
(months)
Outcomes
LR (%) DBF (%) LMD (%) Symptomatic
RN (%)
Asher, 2014 [28] PreOP SRS (47) GTV = PTV NA 14.4 (1 yr) 38.2 (1 yr) NA NA
Patel, 2016 [29] PreOP SRS (66)
Vs.
Postop SRS (114)
GTV = PTV
PTV = cavity +
1–2 mm margin
17.1
13.5
15.9 (1 yr)
12.6 (1 yr)
32 (1 yr)
39.1(1 yr)
3.2 (1 yr)
3.2 (2 yr)
8.3 (1 yr)
16.6 (2 yr)
4.9 (2 yr)
16.4 (2 yr)
Patel, 2017 [44] PreOP SRS (66)
Vs.
Postop WBRT [36]
GTV = PTV
PTV = cavity +
1–2 mm margin
13.9
12.6
24.5 (2 yr)
25.1 (2 yr)
53.2 (2 yr)
45 (2 yr)
3.5 (2 yr)
9 (2 yr)
5.6 (2 yr)
0 (2 yr)
Prabhu, 2018
(Abstract only)
Pre-OP SRS (117) GTV = PTV 17.2 19.9 (1 yr);
25.1 (2 yr)
45.3 (1 yr);
60.2 (2 yr)
4.3 (1 yr);
4.3 (2 yr)
2.6 (1 yr)
4.8 (2 yr)
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humans. We will simultaneously perform an exploratory
analysis regarding histologic and molecular changes after
radiosurgery for specimens removed to determine cor-
relation between response to radiation at tumor margin
and LC. This analysis will potentially provide molecular
prognostic data for local and overall outcomes of
patients with BMs.
Study goals and objectives
Primary objective
To evaluate 6-month in-brain local control utilizing
pre-operative SRS followed by surgical resection for up
to 4 brain metastases.
Secondary objectives
 Overall survival
 Progression free survival
 Distant-in-brain failure
 Rate of leptomeningeal spread
 Rate of radiation necrosis.
Exploratory objectives
Molecular studies to investigate the relationship between
radiation dose and DNA damage in tumor tissue. In
addition, characterization of early histologic and molecu-
lar changes, in terms of gene expression, seen within the
tumor following radiation.
Methods/design
Study design
This is a single-center, single-cohort, single-arm, pro-
spective phase II trial to determine the local control at 6
months utilizing pre-operative SRS followed by surgery
within 1–4 days of radiation treatment in neurologically
symptomatic patients with up to 4 brain metastases.
Study population
Patients with 1–4 metastatic lesions in the brain identi-
fied on a diagnostic brain MRI or CT with at least one
meeting the criteria for surgical resection i.e. symptom-
atic or size > 3 cm, will be identified as potential study
candidates. Amongst the study candidates, patients
meeting the inclusion and exclusion criteria (Table 4)
will be eligible to enroll in the study. Eligible patients
who complete the Informed Consent Process will be reg-
istered in the OnCore® database and assigned a patient
ID number for the clinical study.
Trial status and project duration
The trial is scheduled to recruit 44 patients and is cur-
rently recruiting. The projected duration for the study is
3 years. The time line is outlined in Table 6.
Stereotactic radiosurgery
SRS will be delivered utilizing gamma knife or linear
accelerator-based techniques. With the Leksell Gamma
Knife Perfexion®, Leksell GammaPlan® will be used to gen-
erate the treatment plan with respect to the head frame
coordinate system created by localization. Target volume
and isocenter determination will be based on a brain MRI
with the patient’s head in the stereotactic frame. Linear
accelerator based stereotactic localization will be per-
formed using the Encompass® SRS thermoplastic mask
Table 4 Inclusion and Exclusion Criteria
Inclusion Criteria
1. Radiographically confirmed solid tumor brain metastases
2. Criteria for surgical resection of at least one metastasis per
neurosurgeon discretion
3. A diagnostic MRI Brain or CT Head demonstrating the presence
of 1–4 solid tumor brain metastases and lesion to be resected no
more than 5 cm in any direction, performed within 30 days prior
to stereotactic radiosurgery. If multiple lesions are present, then
the total brain metastases volume can be no more than 30 cm3
excluding the lesion to be resected.
4. For known primary, ds-GPA estimated median survival no less
than 6months
5. For unknown primary, GPA estimated median survival no less
than 6months
6. Surgical candidate per neurosurgeon discretion
7. Surgical resection able to be performed within 1–4 days after
radiosurgery
8. Stereotactic radiosurgery candidate per radiation oncologist
9. ≥ 18 years old at the time of informed consent
10. Ability to provide written informed consent and HIPAA
authorization
11. Platelet count > 100 k/ml, Hgb > 7.5 g/dL, INR < 1.3,
ANC > 1.5 k/ml
12. Patients currently on cytotoxic chemotherapy or immunotherapy
are eligible, not including anti-VEGF therapy
Exclusion Criteria
1. Patients who received anti-VEGF therapy within 6 weeks prior
to enrollment
2. Major medical illnesses or psychiatric impairments, which in the
investigator’s opinion will prevent administration or completion
of the protocol therapy and/or interfere with follow-up
3. Patients with more than 4 brain metastases on MRI Brain or
CT Head
4. Lesion to be resected is more than 5 cm
5. Total volume of metastatic disease more than 30 cm3
excluding lesion to be resected
6. Patients with leptomeningeal metastases documented by MRI
or CSF evaluation
7. Previous whole brain radiation therapy
8. Previous radiation therapy to lesion to be resected
9. Planned adjuvant focal therapy including additional radiation
therapy to the brain
10. Not a surgical candidate per neurosurgeon’s discretion
11. Not a radiosurgical candidate per radiation oncologist’s
discretion
12. Surgery unable to be performed between 1 and 3 days
after radiosurgery
13. Women who are pregnant or nursing are not eligible as
treatment involves unforeseeable risks to the fetus or child
14. Patients who have a known primary and have an estimated
median survival less than 6months per ds-GPA
15. Patients who have an unknown primary and have an estimated
median survival less than 6months per GPA
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immobilization system. The patient will undergo a 1mm
slice thickness helical CT scan that will be fused with the
MRI brain T1-weighted post-contrast axial scan used for
target delineation. The CT-MRI fusion maximum correl-
ation error must be less than 1.5mm.
The prescribed dose will be based on tumor diameter
per RTOG 90–05 dosing criteria with the exception that
the largest lesion diameter to be treated with 15 Gy will
be 5 cm (Table 5). [27] Since it has been shown that
brain metastases up to 4.5 cm can be safely treated with
15 Gy SRS either alone or with WBRT with no reported
toxicity at 2–3 months following treatment. [30]
SRS will be delivered to each lesion that has not previ-
ously undergone treatment. Due to the volumetric sum-
mation constraint for the remaining metastases, no
single, non-resected lesion greater than 4 cm will be
allowed in the study. If any two lesions are within 0.8 to
2 cm of each other, the intervening midplane dose will
not exceed 13 Gy. This may require treating each re-
spective target with a lesser dose than dictated by the
above dosing criteria to minimize toxicity. The dose to
the critical structures, including optic pathway, brain-
stem, cochlea and medulla, must meet constraints as
designated by Task Group 101. [31] If the above con-
straints cannot be met utilizing the prescribed radiosur-
gery dose, then the highest dose to the target volume
will be used such that constraints can be met. This will
be considered a minor deviation.
Surgical resection
At least one of the 4 lesions has to be either larger than
3 cm or symptomatic to meet the surgical resection cri-
teria. One to four days after radiosurgery, the dominant
lesion(s) will be maximally resected and labeled tissue
will be sent to the neuropathology department for clin-
ical diagnosis and radiobiological correlative studies. If
for safety concern or other considerations, gross total
resection is not reached, the residual disease in the
setting of subtotal resection will be closely observed
given that it has been treated with a definitive dose
of SRS, reserving salvage local therapy for cases of
progression. [29] Patients who received subtotal resec-
tion will be recorded and analyzed as well for risk
stratification.
Correlative analysis
For the radiobiological studies, tissues will be examined
for a) pathologic diagnosis b) immunohistochemistry for
immune cell infiltrates and c) mitochondrial histochemis-
try to address DNA damage. In addition, to understand
the effect of radiation dosing on tumor tissue at the mo-
lecular level, RNA and DNA sequencing will be performed
on peripheral and central sites from the tumor specimen
of each patient’s tumor samples. The early cellular gene
expression changes in response to high dose radiation will
be assessed. DNA sequencing and RNA expression will
also be correlated with all clinical outcomes to establish
prognostic molecular classifications. Protein analysis for
apoptotic pathway activation will also be done on tumor
cells to assess radiation induced tumor cell killing.
Response and progression assessment in neuro-oncology
brain metastases (RANO-BM) [32]
Following delivery of SRS and surgical resection, all
patients will be assessed for their clinical performance
status (GPA/ds-GPA/ ECOG performance status/KPS)
as well as toxicity at follow-up intervals as detailed in
Table 6. Serial MRIs will be analyzed per RANO-BM cri-
teria for assessment of LC, DBF and cranial progression
free survival. [32] Initiation or continuation of chemo-
therapy, immunotherapy or other systemic agents is
allowed per medical oncologist discretion.
Leptomeningeal disease and radiation necrosis
Assessment for LMD and RN will be performed using
contrast-enhanced MRI scans. LMD is defined as new
subarachnoid, ventricular or parenchymal enhancing
nodules, focal or diffuse pial enhancement, ependymal,
sulcal, folia or cranial nerve enhancement. [33] RN is
defined as a contrast-enhancing lesion with surrounding
edema within previous radiation treatment fields. MR
spectroscopy and perfusion weighted imaging (PWI)
sequences will be analyzed to differentiate between RN
and recurrent tumor. [34, 35]
General monitoring
For patients presenting with signs and symptoms relat-
able to peri-tumoral edema, dexamethasone will be pre-
scribed at a dose level per clinician judgment. For
patients presenting with seizure, anti-seizure medication
will be prescribed at a dose level per clinician judgment.
No specific type of anti-seizure medication is recom-
mended or prohibited. Subjects will be encouraged to r-
emain in the study and maintain regular follow-up.
Possible reasons for early withdrawal may include, but
are not limited to, the following:
Table 5 Radiosurgery dose criteria
Maximum Tumor Diameter Prescribed Dose
≤ 20mm 24 Gy
21–30 mm 18 Gy
31–40 mm 15 Gy
40–50 mm 15 Gy
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 Subject decides to withdraw from the study. This
decision must be an “independent decision” that is
documented in the source documentation
 The Principal Investigator and/or treating physician
may choose to withdraw a subject from the study if
there are safety or other concerns.
 Subject becomes pregnant.
 Subject non-compliance.
 Subject lost to follow-up.
 Subject death.
Follow-up
Time-to-event analyses will be measured from the date of
completion of radiation therapy (Day 0). As outlined in
Table 6 patients will be followed at 1-month post radiosur-
gery, then at 3month and every 3months thereafter for 2
years. A detailed medical history, toxicity assessment and
physical examination including vital signs will be performed
at each visit. Each follow-up starting from 3month follow
up will also include a MRI with the following sequences:
without contrast, with contrast, FLAIR, DTI and PWI. The
MRI will be analyzed per RANO-BM criteria [32] for as-
sessment of local control, distant in-brain failure and cra-
nial progression free survival. The MRI will also be
analyzed for radiation necrosis and leptomeningeal disease
as discussed in methodology section. Cases concerning for
radiation necrosis will be further analyzed using MR spec-
troscopy. After the 2 year follow up period, subjects will be
followed according to their treating physician per standard
of care approximately every 6months). Patients will con-
tinue to be followed for survival information until death.
All AEs considered related to trial medication will be
followed until resolution, return to baseline, or deemed
clinically insignificant, even if this occurs post-trial.
Safety considerations
Investigators will conduct continuous review of data and
patient safety. Monthly review meetings for moderate risk
trials are required and will include the principal investiga-
tor, clinical research specialist and/or research nurse. Ad-
verse events (AEs) will be recorded from the time of study
intervention and for at least 30 days after treatment discon-
tinuation, regardless of whether or not the event(s) are con-
sidered related to trial medications. Any death occurring
within 30 days after the study intervention will be reported
as a serious adverse event (SAE) regardless of attribution.
AEs will be reported to the IRB within 5 days from becom-
ing aware of the event if they are: [1] unexpected, [2] re-
lated or possibly related to study participation, and [3]
suggests that the research places subject(s) or others at
greater risk of harm than was previously known. SAE re-
ports are entered into OnCore® monthly and reviewed by
Table 6 Study Protocol and follow up timeline
Screening (within
30 days of SRS)
Stereotactic
radiosurgery
Surgery (1–4
days post SRS)
1 Month Follow Upa
(30 days post SRS)
Follow Upb (every
3 m until 2 yrs)
Long Term Follow
Upc (> 2 yr. post SRS)
Radiation oncology consult x
Neurosurgical consult x
Medical History x x x x
Physical Examination x x x x
Vitals x x x x x x
ds-GPA/GPA/ECOG
performance status/KPS
x x x x
Diagnostic MRI Brain or
CT Head
x
MRI Brain Planning Scanf x
WBC, Hgb, platelets,
INR, ANCd
x x
Urine pregnancy test x
Toxicity assessment x x
MRI Braine x x
Tissue collection x
aVariations of +/− 14 days from the scheduled visit are permitted
bVariations of +/− 30 days from the scheduled visit are permitted
cSubjects will be followed at physician’s discretion, approximately every 6months after 2 years post SRS, per standard of care. Any MRI Brain, physical exam or
vitals obtained at these appointments will gathered. However, if these procedures are not performed per standard of care, this will not be a deviation
dRepeating Hgb, platelets, INR and ANC at time of surgery is per discretion of neurosurgeon
eMRI Brain performed at Indiana University will have sequences including contrast, no contrast, FLAIR, DTI and PWI. If patient receives MRI Brain outside of Indiana
University, a minimum of contrast, no contrast and FLAIR will need to be obtained and all sequences mentioned above are encouraged
fVariations of −30 days from the scheduled visit are permitted for linear accelerator based SRS, and may include the baseline screening MRI at the treating
radiation oncologist’s discretion
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the Data Safety Monitoring Committee (DSMC) chair and/
or coordinator monthly. Findings will be reported to the
full DSMC at the time of study review. At any time during
the trial, the study will be closed early if it is the opinion of
the investigators that the risks (or benefits) to the patient
warrant early closure of the study. Alternatively, the DSMC
may initiate suspension or early closure of the study based
on its review of the investigator reports.
Data management
This study will utilize electronic Case Report Form com-
pletion in the OnCore® database. A calendar of events
and required forms are available in OnCore®. The
OnCore® database is a comprehensive, web-based, Clin-
ical Trial Management System (CTMS) which utilizes an
Oracle database. All documents will be kept according
to applicable federal guidelines. Clinical trial data in
OnCore® are periodically monitored by the IU Simon
Cancer Center Data Safety Monitoring Committee.
Quality assurance
Records of IRB review and approval of all documents
pertaining to this study will be kept on file in the Clin-
ical Trials Office and are subject to inspection at any
time during the study. Periodic status reports will be
submitted to the Institutional Review Board at least
yearly, as well as notification of completion of the study
and a final report within 3 months of study completion
or termination. Accrual data will be entered into the IU
Simon Cancer Center OnCore® system. The Protocol
Progress Committee (PPC) reviews study accrual twice
per year while the PPC coordinator reviews accrual
quarterly.
Project Management
Patient recruitment is based on the referral from neurosur-
geons, medical oncologists, radiation oncologist, primary
care physicians, or self-referral. The principal investigators
are responsible for checking eligibility and explaining the
study principles, including detailed experimental schedule,
investigational treatment, potential risks, and benefits. Radi-
ation oncologists, neurosurgeons, and medical oncologists
will be responsible for the consults, clinical treatments and
follow up evaluations for the respective specialties. Patholo-
gists will be performing histochemistry, immunochemistry
and assist on other aspect of correlative studies. Statistical
analysis will be performed by statisticians from the
Department of Biostatistics at Indiana University School of
Medicine.
Statistical analysis
A sample size of 44 patients will provide 82% power with
an alpha = 0.05 to determine if the proportion of patients
with local control at 6months is <= 83% or > = 95%. For
the primary objective of 6-month local control for pre-op-
erative SRS followed by surgical resection of the brain me-
tastases, the proportion of patients who have local control
at 6months will be calculated along with a 95% confidence
interval. Testing the observed proportion against a baseline
6-month local control proportion of 83% at a one-sided
alpha of 5% using a binomial test will be done. The propor-
tion of patients who have in-brain distant failure, radiation
necrosis, and leptomeningeal spread in the evaluated pa-
tients will be summarized and exact binomial 95% confi-
dence intervals will be determined. Additionally, time to
local failure, distant in-brain progression, and overall sur-
vival will be calculated and analyzed using Kaplan-Meier
methods with the medians estimated with a 95% confidence
interval. The probability rates will be provided for 6
months, 1 year, and 2 years. Finally, the tissue biomarkers of
interest in the molecular study will be correlated with
treated lesion location, in-brain local control, in-brain dis-
tant control, and overall survival using Cox proportional
hazards regression. Time dependent ROC curves will be
generated to assess predictive ability.
Discussion
To date, most studies have evaluated the role of SRS
post-operatively in patients with clear indications for
surgical management of BMs. [13, 20] We believe that
pre-operative SRS merits further investigation as this tech-
nique has several clinical and radiobiological advantages,
including precise tumor definition, possible sterilization of
the tumor margin prior to surgical resection leading to
decreased microscopic spread of disease during surgery,
removal of irradiated tissue, and a theoretical radiobio-
logical advantage of intact vasculature optimizing oxygen-
ation. Additionally, all prior SRS studies limit indication of
SRS to lesion < 4 cm in size due to dose related toxicity.
Since we will be resecting the lesion post SRS, we will
include lesions up to 5 cm in size.
We expect that, compared with historic LC rate associ-
ated with post-operative SRS, pre-operative SRS will have a
higher LC rate as well as decreased risk of LMD and symp-
tomatic RN. In terms of radiobiological studies, we expect
differential gene expression profile in the tissue from the
center of the lesion, which receives 50% greater radiation
dose compared to the periphery of the lesion. In addition,
we expect to see higher percentage of immune cell infiltrate
in the radiation treated lesions.
Our exploratory analysis regarding histologic and mo-
lecular changes after radiosurgery will determine if any cor-
relation between immune response to radiation at tumor
margin and local control exists. This may characterize a
group of patients requiring additional therapy after
pre-operative radiosurgery and surgical resection for max-
imal tumor control.
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